Zacks: Analysts Set $25.50 Price Target for Assembly Biosciences, Inc. (ASMB)

Assembly Biosciences, Inc. (NASDAQ:ASMB) has received a consensus broker rating score of 1.00 (Strong Buy) from the two analysts that provide coverage for the stock, Zacks Investment Research reports. Two analysts have rated the stock with a strong buy rating.

Brokers have set a 12-month consensus price objective of $25.50 for the company and are forecasting that the company will post ($0.79) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Assembly Biosciences an industry rank of 173 out of 265 based on the ratings given to its competitors.

Separately, Chardan Capital assumed coverage on Assembly Biosciences in a report on Tuesday, May 30th. They issued a “buy” rating and a $35.00 price objective on the stock.

COPYRIGHT VIOLATION WARNING: “Zacks: Analysts Set $25.50 Price Target for Assembly Biosciences, Inc. (ASMB)” was posted by Community Financial News and is the sole property of of Community Financial News. If you are viewing this piece of content on another publication, it was illegally copied and reposted in violation of United States & international copyright laws. The original version of this piece of content can be read at https://www.com-unik.info/2017/08/12/zacks-analysts-set-25-50-price-target-for-assembly-biosciences-inc-asmb-updated-updated-updated.html.

Hedge funds have recently made changes to their positions in the stock. Acadian Asset Management LLC raised its stake in shares of Assembly Biosciences by 143.4% in the first quarter. Acadian Asset Management LLC now owns 10,325 shares of the biopharmaceutical company’s stock worth $263,000 after buying an additional 6,083 shares during the last quarter. DUPONT CAPITAL MANAGEMENT Corp purchased a new stake in shares of Assembly Biosciences during the first quarter worth about $344,000. Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in shares of Assembly Biosciences during the first quarter worth about $122,000. Parametric Portfolio Associates LLC purchased a new stake in shares of Assembly Biosciences during the first quarter worth about $226,000. Finally, Victory Capital Management Inc. purchased a new stake in shares of Assembly Biosciences during the first quarter worth about $580,000. 68.85% of the stock is currently owned by institutional investors.

Assembly Biosciences (NASDAQ ASMB) traded down 2.25% during mid-day trading on Monday, reaching $21.76. The company’s stock had a trading volume of 48,465 shares. The company’s market capitalization is $377.45 million. The stock has a 50-day moving average price of $23.33 and a 200-day moving average price of $21.01. Assembly Biosciences has a one year low of $5.15 and a one year high of $28.24.

About Assembly Biosciences

Assembly Biosciences, Inc is a biotechnology company. The Company is engaged in developing two platform programs, such as a class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection, and a class of oral synthetic live therapeutics, which are designed to restore health to a dysbiotic microbiome.

Get a free copy of the Zacks research report on Assembly Biosciences (ASMB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

What are top analysts saying about Assembly Biosciences Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Assembly Biosciences Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit